It is effective – long term outcomes show very low recurrence rates for low and intermediate risk prostate cancers It is safe – serious side urinary (2.4%) and gastrointestinal (0.4%) side effect rates are low and comparable to the already historically low rates for IMRT and brachytherapy[3]. It is non-invasive – No cutting, no poking of needles, no insertion of catheters, no anaesthesia required It is convenient – 5 outpatient treatments each taking up to half-an-hour, done over 1 and a half weeks. Normal life can continue before, during and after. It is economical even for those without private insurance coverage – Medisave and medishield can be used for most of the treatment cost, with less cash outlay compared to IMRT.